Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk.

por Bruning, P. F., Bonfrèr, J. M., Hart, A. A.
Publicado 1985

PRAME expression and clinical outcome of breast cancer

por Epping, M T, Hart, A A M, Glas, A M, Krijgsman, O, Bernards, R
Publicado 2008

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

por Weigelt, B, Bosma, A J, Hart, A A M, Rodenhuis, S, van 't Veer, L J
Publicado 2003

The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer

por Kaas, R, Peterse, J L, Hart, A A M, Voogd, A C, Rutgers, E J T, van Leeuwen, F E
Publicado 2003

Tamoxifen, serum lipoproteins and cardiovascular risk.

por Bruning, P. F., Bonfrer, J. M., Hart, A. A., de Jong-Bakker, M., Linders, D., van Loon, J., Nooyen, W. J.
Publicado 1988

Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS

por Bijker, N, Peterse, J L, Fentiman, I S, Julien, J-P, Hart, A A M, Avril, A, Cataliotti, L, Rutgers, E J T
Publicado 2002

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

por Hoebers, F. J. P., Pluim, D., Hart, A. A. M., Verheij, M., Balm, A. J. M., Fons, G., Rasch, C. R. N., Schellens, J. H. M., Stalpers, L. J. A., Bartelink, H., Begg, A. C.
Publicado 2007